Drug Profile
Trimetazidine - Servier
Alternative Names: Adexor; Flavedon; Idaptan; Preductal; S 5016; Trimetazine; Vastarel; Vastarel F; VastinanLatest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Servier
- Class Anti-ischaemics; Cytoprotectives; Hepatoprotectants; Ischaemic heart disorder therapies; Piperazines; Small molecules; Vasodilators
- Mechanism of Action Adenosine triphosphatase inhibitors; Antioxidants; Calcium channel antagonists; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Angina pectoris; Eye disorders; Ischaemic heart disorders; Tinnitus; Vertigo
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
- 22 Jun 2012 The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that trimetazidine is not used for treatment of vertigo, tinnitus or vision disturbance, and the deletion of these indications from the marketing authorisation .